How RGNX Got QURE’d: A Regulatory Regime Change in CNS Gene Therapy

From Exception-Era Approvals to a Unified Framework

Over the past several months, two gene therapy programs targeting devastating, ultra-rare neurologic diseases have experienced what markets reflexively label as “rug pulls.” First came uniQure’s AMT-130 program in Huntington’s disease and more recently, REGENXBIO received a Complete Response Letter (CRL) for RGX-121 in MPS II (Hunter syndrome).

At first glance, these events look unequivocally bearish: two drugs with real biological signal, years of development behind them, and patients with no meaningful alternatives suddenly stalled by regulatory process. Taken together and examined carefully, these developments point to something more subtle and ultimately more constructive: a regulatory regime change in how the FDA is attempting to evaluate and approve direct-to-brain gene therapies (particularly using the Clearpoint Neuro system).

This distinction matters because regime changes are painful in transition, but often bullish for the strongest programs once the framework settles.